scholarly article | Q13442814 |
P2093 | author name string | Shinsuke Inoue | |
Kazuoki Kondo | |||
Makoto Akimoto | |||
Kaori Yoshida | |||
Yoshinobu Nakamaru | |||
Hidetoshi Shimizu | |||
Masae Kakubari | |||
Mai Endo | |||
Tomoko Natori | |||
P2860 | cites work | Treatment of acute ischemic stroke: recent progress | Q28193177 |
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen | Q38153555 | ||
Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies. | Q39945478 | ||
Rate-corrected QT interval: techniques and limitations | Q40788117 | ||
Scientific white paper on concentration-QTc modeling | Q47361141 | ||
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies | Q47782666 | ||
Edaravone and its clinical development for amyotrophic lateral sclerosis | Q47782687 | ||
Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations | Q48033726 | ||
Enabling robust assessment of QTc prolongation in early phase clinical trials | Q48324795 | ||
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis | Q50222465 | ||
Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis | Q50222468 | ||
Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers | Q57155471 | ||
Beat-to-beat QT dynamics in healthy subjects | Q75291873 | ||
Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics | Q88437167 | ||
Edaravone: a new hope for deadly amyotrophic lateral sclerosis | Q89583589 | ||
Edaravone for the treatment of amyotrophic lateral sclerosis | Q91955956 | ||
P577 | publication date | 2020-06-15 | |
P1433 | published in | Clinical pharmacology in drug development | Q27726600 |
P1476 | title | A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects |
Search more.